{"article":{"annotation":{"article_id":"everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026","available_at":"2026-11-20T15:14:38.243651Z","geography_revision":"ef6ee0010dda5fe7b240fd514749b43e214c57da73222d2e40ec83b276dd0977","id":"169df6305666ae86633050c67d012f667d06851707ee745339b072bb94b8d1cc","input_sha256":"e4463071f6f09135d1dc955f37bd6e9efc14616b40c7233551fbea4960d5fd44","limitations":["Rule-derived subjects are candidates, not verified editorial labels or calibrated model probabilities.","Coverage is distinct from event location. Unknown country/city/coordinates remain absent; no automatic geocoding.","Article geometries keep their stated precision and methodology; reproducing them is not independent coordinate verification."],"method":"controlled-rules-v1","places":[{"admin1":null,"city":null,"coordinate_note":null,"coordinate_reference_system":"OGC:CRS84","coordinate_source":null,"country":"CN","evidence":[{"field":"country","language":"en","note":"Explicit preserved editorial country/region; no city or national centroid inferred","source_urls":["https://www.prnewswire.com/apac/news-releases/everest-medicines-announces-first-patient-dosed-in-ascend-phase-2b-trial-of-vis-101-in-wet-amd-302946504.html"]}],"geometry":null,"id":"iso3166-1:CN","kind":"country-or-area","labels":{"ar":"الصين","en":"China","es":"China","fr":"Chine"},"match_status":"candidate","precision":"regional","role":"coverage","uncertainty_m":null}],"rules_sha256":"fb5ad3c27c91cb840f7a0a05f7f64a5cb26ad0374409ff9457f277c7092e22b4","schema_version":1,"subjects":[{"concept_id":"medtop:07000000","confidence":null,"confidence_method":null,"evidence":[{"field":"category+topics","language":"en","note":"Preserved editorial category/topic; broad candidate only","source_urls":["https://www.prnewswire.com/apac/news-releases/everest-medicines-announces-first-patient-dosed-in-ascend-phase-2b-trial-of-vis-101-in-wet-amd-302946504.html"]}],"method":"controlled-rules-v1","rule_id":"health-broad","status":"candidate"}],"taxonomy_revision":"1f2db31d811fca07e99b16d402c10e2cc2965c9df1c7b41d9be348b40a24e7fb","taxonomy_version":"IPTC Media Topics 2026-Q2"},"api_url":"https://newsverum.com/api/v1/articles/everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026?lang=en","category":"health","content":{"key_points":[],"paragraphs":["Everest Medicines announced on 20 November 2026 from Shanghai that the first patient has been dosed in the ASCEND study, a randomized Phase 2b clinical trial evaluating its investigational ophthalmology candidate VIS-101 in wet age-related macular degeneration. The study is being conducted in China in partnership with Visara, Inc., a majority-owned ophthalmology subsidiary of NovaBridge Biosciences. Everest Medicines stated that the trial is designed to compare two dose levels of VIS-101 directly against aflibercept, an established anti-VEGF standard of care, to select dosing for a global Phase 3 program.","Registered on ClinicalTrials.gov as NCT07798375, ASCEND is a randomized, quadruple-masked, active-controlled, head-to-head Phase 2b trial planned to enrol approximately 244 treatment-naïve patients with wet age-related macular degeneration in China. Participants are randomized to receive either 6 mg VIS-101, 9 mg VIS-101 or 2 mg aflibercept. All treatment arms begin with three monthly loading injections, after which patients can be retreated up to Month 9 according to identical protocol-specified retreatment criteria across groups.","The trial's primary efficacy endpoint is the change in best-corrected visual acuity from baseline to Week 36 compared with aflibercept administered every eight weeks. Alongside visual acuity outcomes and safety monitoring, the ASCEND protocol is structured to assess initial treatment durability, including whether VIS-101 can sustain disease control across intervals of up to seven months following the three initial loading doses. Everest Medicines said findings from the dose-determining trial will guide dose selection for global Phase 3 development, which is planned to begin as early as 2027.","VIS-101, also identified in development records as AM712 or ASKG712, is a bispecific, tetravalent dual inhibitor targeting both vascular endothelial growth factor A and angiopoietin-2. The molecule is being developed for retinal vascular disorders including wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion. According to Everest Medicines, its tetravalent molecular architecture provides additional binding sites intended to increase binding affinity and avidity against both targets to support rapid visual responses and longer intervals between intravitreal injections.","Prior to launching ASCEND, VIS-101 completed initial safety and dose-escalation studies in both the United States and China, followed by a randomized, dose-ranging Phase 2a study in China registered as NCT05456828. Everest Medicines reported that in the Phase 2a study, VIS-101 demonstrated rapid and durable responses alongside a favorable safety profile in wet age-related macular degeneration, with approximately 50 percent of patients in the 6 mg treatment-naïve cohort remaining retreatment-free six months after their final loading injection.","The commercial and regional development framework for VIS-101 rests on a licensing agreement signed on 30 October 2025 between Everest Medicines and Visara. Under that agreement, Everest acquired an exclusive license to develop, manufacture and commercialize VIS-101 across Greater China, Singapore, South Korea and selected Southeast Asian countries. Everest Medicines operates a commercial-scale manufacturing facility in Jiashan in Zhejiang Province, maintaining a good manufacturing practice quality system aligned with Chinese, European Union and World Health Organization standards.","In explaining the clinical rationale, Everest Medicines cited published epidemiological estimates indicating that wet age-related macular degeneration affects more than 20 million people worldwide. Within China, the company stated that the prevalent population living with age-related macular degeneration and diabetic macular edema exceeds 15 million people, with approximately 600,000 new cases emerging each year, while only about 500,000 patients currently receive active treatment. Frequent clinic visits for intravitreal eye injections remain a widely cited barrier to long-term adherence.","Everest Medicines chief executive officer Rogers Yongqing Luo said patients with wet age-related macular degeneration and other retinal vascular diseases continue to face a heavy treatment burden. He described dosing the first patient in ASCEND as an important step toward testing whether VIS-101 can deliver longer intervals between injections and sustained disease control compared with an established standard of care, adding that the company's regional clinical and commercial infrastructure across China and Asia will support development.","VIS-101 remains an investigational biologic without marketing authorization in any jurisdiction, and the announcement on 20 November 2026 marks the start of Phase 2b treatment rather than a readout of comparative efficacy. Whether the 6 mg or 9 mg regimen matches or improves upon aflibercept at Week 36 while maintaining safety and extended retreatment intervals will only become clear once the 244-patient cohort completes follow-up. Any Phase 3 initiation in 2027 remains contingent on ASCEND results and regulatory review."],"sections":[]},"corrections":[],"country":"CN","data":{"blocks":[{"description":{"ar":"معايير مختارة لتجربة ASCEND للمرحلة 2b وبيانات ديمومة المرحلة 2a وتقديرات انتشار التنكس البقعي التي أوردتها إيفريست ميديسينز.","de":"Ausgewählte Parameter der Phase-2b-Studie ASCEND, Phase-2a-Daten zur Wirkdauer und epidemiologische Schätzungen von Everest Medicines.","en":"Selected ASCEND Phase 2b trial parameters, Phase 2a durability data and regional wet AMD prevalence estimates cited by Everest Medicines.","es":"Parámetros seleccionados del ensayo de fase 2b ASCEND, datos de durabilidad de fase 2a y estimaciones epidemiológicas citadas por Everest Medicines.","fr":"Paramètres sélectionnés de l'essai de phase 2b ASCEND, données de durabilité de phase 2a et estimations épidémiologiques citées par Everest Medicines.","pt":"Parâmetros selecionados do ensaio de fase 2b ASCEND, dados de durabilidade de fase 2a e estimativas epidemiológicas citadas pela Everest Medicines.","tr":"Everest Medicines tarafından aktarılan seçilmiş ASCEND Faz 2b parametreleri, Faz 2a dayanıklılık verileri ve bölgesel yaş tip AMD prevalans tahminleri."},"id":"reported-figures","items":[{"basis":"target","label":{"ar":"العدد المخطط للمرضى في تجربة ASCEND للمرحلة 2b في الصين","de":"Geplante Teilnehmerzahl in der Phase-2b-Studie ASCEND in China","en":"Planned enrolment in ASCEND Phase 2b wet AMD trial in China","es":"Reclutamiento previsto en el ensayo de fase 2b ASCEND en China","fr":"Effectif prévu dans l'essai de phase 2b ASCEND en Chine","pt":"Recrutamento previsto no ensaio de fase 2b ASCEND na China","tr":"Çin'deki ASCEND Faz 2b yaş tip AMD çalışmasında planlanan hasta sayısı"},"measure":{"aggregation":"stock","frequency":"irregular","geography":"china","id":"g20261120-d7-everest-1","periodRole":"announcement-date","unitCode":"count"},"period":"2026-11-20","unit":"patients","value":244,"valueQualifier":"approximate"},{"basis":"observed","label":{"ar":"أسبوع تقييم نقطة النهاية الأساسية للفعالية في دراسة ASCEND","de":"Bewertungszeitpunkt des primären Wirksamkeitsendpunkts in ASCEND","en":"Primary efficacy endpoint assessment time in ASCEND","es":"Semana de evaluación del criterio principal de eficacia en ASCEND","fr":"Semaine d'évaluation du critère principal d'efficacité dans ASCEND","pt":"Semana de avaliação do parâmetro principal de eficácia no ASCEND","tr":"ASCEND çalışmasında birincil etkinlik değerlendirme haftası"},"measure":{"aggregation":"unspecified","frequency":"irregular","geography":"china","id":"g20261120-d7-everest-2","periodRole":"announcement-date","unitCode":"week"},"period":"2026-11-20","unit":"weeks","value":36},{"basis":"observed","label":{"ar":"نسبة المرضى غير المحتاجين لإعادة العلاج بعد 6 أشهر في مجموعة 6 ملغ بالمرحلة 2a","de":"Anteil der 6-mg-Kohorte in Phase 2a ohne erneute Behandlung nach 6 Monaten","en":"Phase 2a 6 mg treatment-naïve cohort retreatment-free at 6 months","es":"Porcentaje de la cohorte 6 mg de fase 2a sin retratamiento a los 6 meses","fr":"Part de la cohorte 6 mg de phase 2a sans retraitement à 6 mois","pt":"Percentagem da coorte de 6 mg na fase 2a sem retratamento aos 6 meses","tr":"Faz 2a 6 mg tedavi görmemiş grupta 6. ayda yeniden tedavi gerektirmeyen oran"},"measure":{"aggregation":"rate","frequency":"irregular","geography":"china","id":"g20261120-d7-everest-3","periodRole":"announcement-date","unitCode":"percent"},"period":"2026-11-20","unit":"percent","value":50,"valueQualifier":"approximate"},{"basis":"estimate","label":{"ar":"العدد السنوي المقدر للحالات الجديدة من التنكس البقعي والوذمة السكرية في الصين","de":"Geschätzte jährliche Neuerkrankungen an AMD und DMÖ in China","en":"Estimated annual new AMD and DME cases in China","es":"Casos nuevos anuales estimados de DMAE y EMD en China","fr":"Nombre annuel estimé de nouveaux cas de DMLA et d'OMD en Chine","pt":"Novos casos anuais estimados de DMRI e EMD na China","tr":"Çin'de tahmini yıllık yeni AMD ve DME vaka sayısı"},"measure":{"aggregation":"flow","frequency":"irregular","geography":"china","id":"g20261120-d7-everest-4","periodRole":"announcement-date","unitCode":"count"},"period":"2026-11-20","unit":"cases","value":600000,"valueQualifier":"approximate"},{"basis":"estimate","label":{"ar":"العدد المقدر لمرضى التنكس البقعي والوذمة السكرية المتلقين للعلاج حالياً في الصين","de":"Geschätzte Zahl derzeit behandelter AMD- und DMÖ-Patienten in China","en":"Estimated AMD and DME patients currently receiving treatment in China","es":"Pacientes estimados con DMAE y EMD que reciben tratamiento actualmente en China","fr":"Nombre estimé de patients atteints de DMLA et d'OMD actuellement traités en Chine","pt":"Doentes estimados com DMRI e EMD atualmente em tratamento na China","tr":"Çin'de halen tedavi alan tahmini AMD ve DME hasta sayısı"},"measure":{"aggregation":"stock","frequency":"irregular","geography":"china","id":"g20261120-d7-everest-5","periodRole":"announcement-date","unitCode":"count"},"period":"2026-11-20","unit":"patients","value":500000,"valueQualifier":"approximate"}],"methodology":{"ar":"تحتفظ الأرقام بتصميم الدراسة والسكان والنطاق والتعريفات التي يحددها المصدر، وتُصنف الأهداف وتقديرات الانتشار بحسب أساسها.","de":"Die Zahlen behalten Studiendesign, Bezugsgruppe, Umfang und Definitionen der Quelle bei. Ziele und Schätzungen sind nach ihrer Grundlage gekennzeichnet.","en":"Figures retain the source's stated trial design, population, scope and definitions. Targets and prevalence estimates are labeled by basis. No missing value is inferred.","es":"Las cifras conservan el diseño, la población, el alcance y las definiciones indicados por la fuente. Objetivos y estimaciones se identifican según su base.","fr":"Les chiffres conservent le protocole, la population, le périmètre et les définitions indiqués par la source. Objectifs et estimations sont qualifiés selon leur base.","pt":"Os valores mantêm o desenho, a população, o âmbito e as definições indicados pela fonte. Metas e estimativas são identificadas segundo a respetiva base.","tr":"Rakamlar kaynağın belirttiği çalışma tasarımı, nüfus, kapsam ve tanımları korur. Hedefler ve prevalans tahminleri dayanaklarına göre etiketlenir. Eksik değerler çıkarımla tamamlanmaz."},"sourceUrls":["https://www.prnewswire.com/apac/news-releases/everest-medicines-announces-first-patient-dosed-in-ascend-phase-2b-trial-of-vis-101-in-wet-amd-302946504.html"],"title":{"ar":"الأرقام الرئيسية المعلنة","de":"Wichtige gemeldete Kennzahlen","en":"Key reported figures","es":"Cifras clave comunicadas","fr":"Principaux chiffres déclarés","pt":"Principais valores reportados","tr":"Bildirilen temel rakamlar"},"type":"metrics","updatedAt":"2026-11-20T14:30:00Z"}],"version":1},"data_downloads":[{"formats":{"csv":"https://newsverum.com/api/v1/articles/everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026/data/reported-figures?lang=en&format=csv","json":"https://newsverum.com/api/v1/articles/everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026/data/reported-figures?lang=en&format=json"},"id":"reported-figures"}],"data_types":["metrics"],"editorial_illustration":{"alt":"Conceptual illustration of public health, research and connected data.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"en","scope":"topic","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"event_id":"event-5a1dc8d4-7af5-5d4c-b78e-68ea7857604f","event_period":"2026-11-20","event_period_basis":"event-or-reference-period","id":"everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026","image":null,"importance":0.6,"language":"en","modified_at":"2026-11-20T15:14:29+00:00","publication_basis":"publication-record","published_at":"2026-11-20T15:14:29+00:00","reading_minutes":4,"region":"world","relations":[],"section_illustration":{"alt":"Conceptual illustration of public health, research and connected data.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"en","scope":"section","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"slug":"everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026","sources":[{"checkedAt":"2026-11-20","name":"Everest Medicines, First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD","publishedAt":"2026-11-20","url":"https://www.prnewswire.com/apac/news-releases/everest-medicines-announces-first-patient-dosed-in-ascend-phase-2b-trial-of-vis-101-in-wet-amd-302946504.html"}],"summary":"Everest Medicines announced on 20 November 2026 that the first patient was treated in China in the 244-patient Phase 2b ASCEND trial comparing VIS-101 against 2 mg aflibercept in wet age-related macular degeneration, ahead of a planned 2027 global Phase 3 program.","text":"Everest Medicines announced on 20 November 2026 that the first patient was treated in China in the 244-patient Phase 2b ASCEND trial comparing VIS-101 against 2 mg aflibercept in wet age-related macular degeneration, ahead of a planned 2027 global Phase 3 program.\n\nEverest Medicines announced on 20 November 2026 from Shanghai that the first patient has been dosed in the ASCEND study, a randomized Phase 2b clinical trial evaluating its investigational ophthalmology candidate VIS-101 in wet age-related macular degeneration. The study is being conducted in China in partnership with Visara, Inc., a majority-owned ophthalmology subsidiary of NovaBridge Biosciences. Everest Medicines stated that the trial is designed to compare two dose levels of VIS-101 directly against aflibercept, an established anti-VEGF standard of care, to select dosing for a global Phase 3 program.\n\nRegistered on ClinicalTrials.gov as NCT07798375, ASCEND is a randomized, quadruple-masked, active-controlled, head-to-head Phase 2b trial planned to enrol approximately 244 treatment-naïve patients with wet age-related macular degeneration in China. Participants are randomized to receive either 6 mg VIS-101, 9 mg VIS-101 or 2 mg aflibercept. All treatment arms begin with three monthly loading injections, after which patients can be retreated up to Month 9 according to identical protocol-specified retreatment criteria across groups.\n\nThe trial's primary efficacy endpoint is the change in best-corrected visual acuity from baseline to Week 36 compared with aflibercept administered every eight weeks. Alongside visual acuity outcomes and safety monitoring, the ASCEND protocol is structured to assess initial treatment durability, including whether VIS-101 can sustain disease control across intervals of up to seven months following the three initial loading doses. Everest Medicines said findings from the dose-determining trial will guide dose selection for global Phase 3 development, which is planned to begin as early as 2027.\n\nVIS-101, also identified in development records as AM712 or ASKG712, is a bispecific, tetravalent dual inhibitor targeting both vascular endothelial growth factor A and angiopoietin-2. The molecule is being developed for retinal vascular disorders including wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion. According to Everest Medicines, its tetravalent molecular architecture provides additional binding sites intended to increase binding affinity and avidity against both targets to support rapid visual responses and longer intervals between intravitreal injections.\n\nPrior to launching ASCEND, VIS-101 completed initial safety and dose-escalation studies in both the United States and China, followed by a randomized, dose-ranging Phase 2a study in China registered as NCT05456828. Everest Medicines reported that in the Phase 2a study, VIS-101 demonstrated rapid and durable responses alongside a favorable safety profile in wet age-related macular degeneration, with approximately 50 percent of patients in the 6 mg treatment-naïve cohort remaining retreatment-free six months after their final loading injection.\n\nThe commercial and regional development framework for VIS-101 rests on a licensing agreement signed on 30 October 2025 between Everest Medicines and Visara. Under that agreement, Everest acquired an exclusive license to develop, manufacture and commercialize VIS-101 across Greater China, Singapore, South Korea and selected Southeast Asian countries. Everest Medicines operates a commercial-scale manufacturing facility in Jiashan in Zhejiang Province, maintaining a good manufacturing practice quality system aligned with Chinese, European Union and World Health Organization standards.\n\nIn explaining the clinical rationale, Everest Medicines cited published epidemiological estimates indicating that wet age-related macular degeneration affects more than 20 million people worldwide. Within China, the company stated that the prevalent population living with age-related macular degeneration and diabetic macular edema exceeds 15 million people, with approximately 600,000 new cases emerging each year, while only about 500,000 patients currently receive active treatment. Frequent clinic visits for intravitreal eye injections remain a widely cited barrier to long-term adherence.\n\nEverest Medicines chief executive officer Rogers Yongqing Luo said patients with wet age-related macular degeneration and other retinal vascular diseases continue to face a heavy treatment burden. He described dosing the first patient in ASCEND as an important step toward testing whether VIS-101 can deliver longer intervals between injections and sustained disease control compared with an established standard of care, adding that the company's regional clinical and commercial infrastructure across China and Asia will support development.\n\nVIS-101 remains an investigational biologic without marketing authorization in any jurisdiction, and the announcement on 20 November 2026 marks the start of Phase 2b treatment rather than a readout of comparative efficacy. Whether the 6 mg or 9 mg regimen matches or improves upon aflibercept at Week 36 while maintaining safety and extended retreatment intervals will only become clear once the 244-patient cohort completes follow-up. Any Phase 3 initiation in 2027 remains contingent on ASCEND results and regulatory review.","title":"Everest Medicines doses first patient in ASCEND Phase 2b trial of VIS-101 for wet AMD","topics":[],"translations":[{"api_url":"https://newsverum.com/api/v1/articles/everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026?lang=tr","language":"tr","url":"https://newsverum.com/tr/news/everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026"},{"api_url":"https://newsverum.com/api/v1/articles/everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026?lang=en","language":"en","url":"https://newsverum.com/en/news/everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026"},{"api_url":"https://newsverum.com/api/v1/articles/everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026?lang=ar","language":"ar","url":"https://newsverum.com/ar/news/everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026"},{"api_url":"https://newsverum.com/api/v1/articles/everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026?lang=fr","language":"fr","url":"https://newsverum.com/fr/news/everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026"},{"api_url":"https://newsverum.com/api/v1/articles/everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026?lang=es","language":"es","url":"https://newsverum.com/es/news/everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026"},{"api_url":"https://newsverum.com/api/v1/articles/everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026?lang=de","language":"de","url":"https://newsverum.com/de/news/everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026"},{"api_url":"https://newsverum.com/api/v1/articles/everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026?lang=pt","language":"pt","url":"https://newsverum.com/pt/news/everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026"}],"url":"https://newsverum.com/en/news/everest-medicines-first-patient-dosed-ascend-phase-2b-vis-101-wet-amd-2026"},"version":"1"}
